Vitamin A deficiency indicating as low expression of LRAT may be a novel biomarker of primary hypertension by Xiaohua Liang (535684)

Data_Sheet_1_Assessment of the Safety and Therapeutic Benefits of Convalescent Plasma in COVID-19 Treatment: A Systematic Review and Meta-Analysis.docx by Daniela Ferreira Barreira (10527662)

“…<p>Background: The coronavirus disease (COVID-19), caused by the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), prompted a global health crisis, with no available specific treatments. …”

Fig 9 - by Yi-xiao Liu (14769126)

Image_1_High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib.pdf by Alessio Amatu (6947912)

“…Circulating methylated DNA (cmDNA) assessed by a five-gene panel was previously associated with outcome in chemotherapy treated mCRC patients. …”

Table_1_High Circulating Methylated DNA Is a Negative Predictive and Prognostic Marker in Metastatic Colorectal Cancer Patients Treated With Regorafenib.pdf by Alessio Amatu (6947912)

“…Circulating methylated DNA (cmDNA) assessed by a five-gene panel was previously associated with outcome in chemotherapy treated mCRC patients. …”

Early reduction in total cholesterol to high-density lipoprotein cholesterol ratio predicts hydroxychloroquine efficacy in treating IgA nephropathy by Yaotong Shi (19511899)

Datasheet1_Cardioprotective effects of shock wave therapy: A cardiac magnetic resonance imaging study on acute ischemia-reperfusion injury.pdf by Lorena Petrusca (13783213)

“…After reperfusion, left ventricular ejection fraction (LVEF) remained significantly decreased in controls (39.9 ± 4% at LR vs. 60 ± 5% at baseline (p = 0.02). …”

Oscillatory Dynamics Supporting Semantic Cognition: MEG Evidence for the Contribution of the Anterior Temporal Lobe Hub and Modality-Specific Spokes - Fig 1 by Giovanna Mollo (3633013)

The microbiome composition differences in the infected and uninfected group as well as the log linear discriminant analysis (LDA) effect size quantifies the degree to which each li... by Xi-Meng Sun (17721428)

Image_5_Ruxolitinib does not completely abrogate the functional capabilities of TLR4/9 ligand-activated NK cells.jpeg by Carmen Mestre-Durán (7121327)

“…Only the highest doses of ruxolitinib led to a decrease in the pro-inflammatory cytokines tumor necrosis factor α, interferon-γ, interleukin-6, and interleukin-1β. …”

Most of thyroid specific transcripts were not affected in 5 days old Tg(Cre/+);Dicer^flox/flox mice. by Wendy Rodriguez (189202)

“…Nevertheless, we observed a slight decrease of Pax8, FoxE1 and Tg mRNA level in Tg(Cre/+); Dicer^flox/flox (−/−) in comparison to Dicer^flox/flox (+/+) mice.…”

Time-frequency plots for each cortical site (ATL, FG, and CS) are presented in each column. by Giovanna Mollo (3633013)

Xenografting of cryopreserved human ovarian tissue. by Vladimir Isachenko (327750)

Self-Powered Biosensing System with Multivariate Signal Amplification for Real-Time Amplified Detection of PDGF-BB by Futing Wang (14851840)

“…When PDGF-BB is present, a binding interaction between the target and the aptamer, i.e., PDGF-BB/Apt, corresponding to the “off” state for HCR, results in a decrease of <i>E</i>^OCV. …”

Self-Powered Biosensing System with Multivariate Signal Amplification for Real-Time Amplified Detection of PDGF-BB by Futing Wang (14851840)

“…When PDGF-BB is present, a binding interaction between the target and the aptamer, i.e., PDGF-BB/Apt, corresponding to the “off” state for HCR, results in a decrease of <i>E</i>^OCV. …”

Self-Powered Biosensing System with Multivariate Signal Amplification for Real-Time Amplified Detection of PDGF-BB by Futing Wang (14851840)

“…When PDGF-BB is present, a binding interaction between the target and the aptamer, i.e., PDGF-BB/Apt, corresponding to the “off” state for HCR, results in a decrease of <i>E</i>^OCV. …”

Table_8_Omega 3 supplementation reduces C-reactive protein, prostaglandin E2 and the granulocyte/lymphocyte ratio in heavy smokers: An open-label randomized crossover trial.DOCX by Ingrid Elisia (3214848)

“…Objectives<p>Given the current controversy concerning the efficacy of omega 3 supplements at reducing inflammation, we evaluated the safety and efficacy of omega 3 on reducing inflammation in people with a 6-year lung cancer risk >1.5% and a C reactive protein (CRP) level >2 mg/L in a phase IIa cross-over study.…”

Presentation_1_Omega 3 supplementation reduces C-reactive protein, prostaglandin E2 and the granulocyte/lymphocyte ratio in heavy smokers: An open-label randomized crossover trial.... by Ingrid Elisia (3214848)

“…Objectives<p>Given the current controversy concerning the efficacy of omega 3 supplements at reducing inflammation, we evaluated the safety and efficacy of omega 3 on reducing inflammation in people with a 6-year lung cancer risk >1.5% and a C reactive protein (CRP) level >2 mg/L in a phase IIa cross-over study.…”

Table_4_Omega 3 supplementation reduces C-reactive protein, prostaglandin E2 and the granulocyte/lymphocyte ratio in heavy smokers: An open-label randomized crossover trial.DOCX by Ingrid Elisia (3214848)

“…Objectives<p>Given the current controversy concerning the efficacy of omega 3 supplements at reducing inflammation, we evaluated the safety and efficacy of omega 3 on reducing inflammation in people with a 6-year lung cancer risk >1.5% and a C reactive protein (CRP) level >2 mg/L in a phase IIa cross-over study.…”

Table_6_Omega 3 supplementation reduces C-reactive protein, prostaglandin E2 and the granulocyte/lymphocyte ratio in heavy smokers: An open-label randomized crossover trial.DOCX by Ingrid Elisia (3214848)

“…Objectives<p>Given the current controversy concerning the efficacy of omega 3 supplements at reducing inflammation, we evaluated the safety and efficacy of omega 3 on reducing inflammation in people with a 6-year lung cancer risk >1.5% and a C reactive protein (CRP) level >2 mg/L in a phase IIa cross-over study.…”